CSL (CSL) investor relations material

Opening remarks and agenda

• Hybrid AGM opened with a quorum; agenda covered FY 2026 reports, director elections, the remuneration report and shareholder questions.

• Resolutions were voted on by poll, with participation available in person or online.

Financial performance review

• FY 2026 revenue was US$15.8bn, up 1%; underlying NPATA was US$3.1bn, up 2%, and underlying NPAT was US$2.8bn, up 3%.

• Reported NPAT was a US$2.6bn loss, including US$0.8bn in pre-tax restructuring costs and US$7.1bn in impairment and related costs.

• Cash flow from operations was US$3.5bn; FY 2026 cost savings were US$176m, and a US$1bn buyback was completed.

• FY 2027 guidance was reaffirmed: revenue in line with FY 2026 at constant currency and underlying NPAT growth of ~5% at constant currency.

• Net debt to EBITDA was 1.8x; leverage remained within the 1.5x–2.0x target range, with an A$1.1bn buyback planned for FY 2027.

Board and executive committee updates

• Deborah Waterhouse was appointed CEO and Managing Director from 1 February; Gordon Naylor was selected as Chair-elect, succeeding Brian McNamee after his planned 31 March retirement.

• Carolyn Hewson stood for re-election and Gordon Naylor for election; Costa Saroukos also stood for election or re-election, with board support for the nominees.

• Hewson said she would support CEO and Chair transitions over the next 12–18 months as Senior Independent Director if re-elected, then intends to retire from the board.

• Diego Sacristan became Chief Commercial Officer in July, leading Behring and Vifor commercial and medical functions; Amy Van Buren became Chief People Officer in April.